The Prognostic, Predictive and Clinicopathological Implications of KRT81/HNF1A- and GATA6-Based Transcriptional Subtyping in Pancreatic Cancer
Biomolecules · 2025
DOI: 10.3390/biom15030426 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecules, 2025. Verfasst von Michael Guenther und 8 weiteren Autor:innen. Beteiligte Einrichtung: Innpath Institute of Pathology, Tirol Kliniken, 6020 Innsbruck, Austria. Hauptthemen laut MEDLINE: GATA6 Transcription Factor, Pancreatic Neoplasms, Hepatocyte Nuclear Factor 1-alpha, Carcinoma, Pancreatic Ductal. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Transcriptional subtypes of pancreatic ductal adenocarcinoma (PDAC) based on the expression of hallmark genes may have prognostic implications and potential predictive functions. The two most employed subtyping markers assess the combined expression of KRT81 and HNF1A or of GATA6 alone, which can be detected by immunohistochemistry (IHC). This study aimed to determine the prognostic or predictive impact of both subtyping marker panels in two large cohorts of advanced and resected pancreatic ductal adenocarcinoma (PDAC) patients.
Methods
Transcriptional subtypes were determined by combining the expression of KRT81/HNF1A or assessing GATA6 expression alone by IHC in samples of two independent PDAC patient cohorts (advanced PDAC n = 139 and resected PDAC n = 411) as well as in 57 matched primary tumors and their corresponding metastases. RNAseq-based expression data of 316 resected PDAC patients was analyzed for validation.
Results
Transcriptional subtypes widely overlapped in both marker panels (χ2 p < 0.001) but switched during disease progression in up to 31.6% of patients. They had a modest impact on the patients’ prognosis in both cohorts, with longer overall survival (OS) for patients with KRT81−/HNF1A+ or GATA6+ tumors but better progression-free survival (PFS) and disease-free survival (DFS) in patients with KRT81+/GATA6− tumors treated with palliative or adjuvant gemcitabine-based chemotherapy. RNAseq expression data confirmed the findings.
Conclusions
Transcriptional subtypes have differential responses to palliative and adjuvant gemcitabine-based chemotherapy and may change during disease progression. Both employed subtyping marker panels are equivalent and may be used to inform clinical therapy decisions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Innpath Institute of Pathology, Tirol Kliniken, 6020 Innsbruck, Austria.
- Institute of Pathology, Faculty of Medicine, Ludwig-Maximilians-University, 80337 Munich, Germany.
- Department of Hematology and Oncology, München Klinik Neuperlach, 81737 Munich, Germany.
- Department of Internal Medicine III, Grosshadern University Hospital, Ludwig-Maximilians-University, 81377 Munich, Germany.
- Institute of Pathology, Neuropathology and Molecular Pathology, Medical University Innsbruck, 6020 Innsbruck, Austria.
ORCID-Profile: Michael Guenther, Steffen Ormanns
Zitieren
APA
Guenther, M., Surendran, S. A., Steinke, L. M., Liou, I., Palm, M. A., Heinemann, V., Haas, M., Boeck, S., & Ormanns, S. (2025). The Prognostic, Predictive and Clinicopathological Implications of KRT81/HNF1A- and GATA6-Based Transcriptional Subtyping in Pancreatic Cancer. Biomolecules. https://doi.org/10.3390/biom15030426
Vancouver
Guenther M, Surendran SA, Steinke LM, Liou I, Palm MA, Heinemann V, et al. The Prognostic, Predictive and Clinicopathological Implications of KRT81/HNF1A- and GATA6-Based Transcriptional Subtyping in Pancreatic Cancer. Biomolecules. 2025. doi:10.3390/biom15030426
BibTeX
@article{Guenther2025,
author = {Guenther, Michael and Surendran, Sai Agash and Steinke, Lea Margareta and Liou, Iduna and Palm, Melanie Alexandra and Heinemann, Volker and Haas, Michael and Boeck, Stefan and Ormanns, Steffen},
title = {The Prognostic, Predictive and Clinicopathological Implications of KRT81/HNF1A- and GATA6-Based Transcriptional Subtyping in Pancreatic Cancer},
journal = {Biomolecules},
year = {2025},
doi = {10.3390/biom15030426}
}
EUVIMED